Avenue Therapeutics Inc represents values of innovation, integrity, and patient-centered care in the pharmaceutical industry. The company is committed to developing and commercializing innovative therapies to address unmet medical needs. Their corporate philosophy revolves around scientific excellence, collaboration with key stakeholders, and a deep dedication to improving the lives of patients. By staying at the forefront of research and development, Avenue Therapeutics strives to deliver transformative solutions while adhering to the highest ethical standards. With a focus on delivering value to patients, healthcare providers, and shareholders, Avenue Therapeutics Inc aims to make a positive impact in the healthcare landscape.

Avenue Therapeutics Inc is primarily present in the United States.

Avenue Therapeutics Inc has achieved significant milestones since its establishment. The company successfully completed a pivotal Phase 3 study for its lead product, intravenous (IV) tramadol for the management of moderate to moderately severe postoperative pain. Additionally, Avenue Therapeutics Inc received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) which outlined certain requirements to support the New Drug Application (NDA) for IV tramadol. The company continues to work towards meeting these requirements and is committed to advancing the development of IV tramadol as a potential non-opioid treatment option for patients in need.

Avenue Therapeutics Inc is a pharmaceutical company specializing in the development and commercialization of intravenous (IV) pain management medications. Founded in 2015, the company focuses on providing innovative treatment options for patients suffering from acute pain following surgery or medical procedures. Avenue Therapeutics Inc aims to improve the standard of care in pain management through its unique drug formulations and delivery methods. With a dedicated team of experts and a strong commitment to research and development, the company is actively working towards addressing the unmet needs in pain management and improving patient outcomes. Avenue Therapeutics Inc is poised to make a significant impact in the healthcare industry.

The main competitors of Avenue Therapeutics Inc in the market are pharmaceutical companies such as Pacira Pharmaceuticals, Mallinckrodt Pharmaceuticals, and Heron Therapeutics.

Avenue Therapeutics Inc is primarily active in the pharmaceutical industry.

The business model of Avenue Therapeutics Inc is focused on developing and commercializing intravenous (IV) tramadol, a potential non-opioid pain medication. Tramadol is a centrally acting analgesic that has been approved for the management of moderate to moderately severe pain. Avenue Therapeutics aims to address the unmet need for non-opioid pain relief options through the development and commercialization of IV tramadol. By leveraging their expertise and research in pain management, Avenue Therapeutics is committed to providing patients with effective and safer pain management alternatives while reducing the risks associated with opioid-related medications.

Avenue Therapeutics Коефіцієнт P/E становить -0,04.

Коефіцієнт виручки від продажу Avenue Therapeutics становить 0.

АлеАкції індекс якості для Avenue Therapeutics складає 2/10.

Дохід зараз не можна розрахувати для Avenue Therapeutics.

очікувана Avenue Therapeutics прибуток становить -9,28 млн. USD.

Avenue Therapeutics Inc. is an innovative pharmaceutical company specializing in the development and marketing of analgesics. The company focuses on the needs of patients requiring rapid pain relief, such as after surgeries or severe injuries. Its main product is Tramadol, an opioid analgesic used intravenously and as a supportive therapy for moderate to severe pain. Avenue Therapeutics aims to bring its products to market quickly through a combination of in-house development and acquisitions. It works closely with healthcare providers and utilizes a multi-channel marketing strategy. Research and development are also important components of the company's business model. Overall, Avenue Therapeutics is focused on meeting the pain relief needs of patients and aims to increase its market share through its diversified products and services.

Avenue Therapeutics виплачує дивіденд у розмірі 0 USD, розподілений на виплати протягом року.

Дивіденди для Avenue Therapeutics на даний момент не можуть бути розраховані, або компанія не виплачує дивіденди.

ISIN Avenue Therapeutics є US05360L2051.

WKN Avenue Therapeutics становить A2JH92.

Тікер Avenue Therapeutics це ATXI.

Протягом останніх 12 місяців компанія Avenue Therapeutics виплатила дивіденд у розмірі . Це відповідає приблизній дивідендній дохідності . Очікується, що протягом наступних 12 місяців Avenue Therapeutics виплатить дивіденд у розмірі 0 USD.

Дивідендна дохідність Avenue Therapeutics наразі становить .

Avenue Therapeutics виплачує дивіденди щоквартально. Вони виплачуються у місяцях .

Avenue Therapeutics протягом останніх 0 років щороку виплачував дивіденди.

На наступні 12 місяців очікується дивіденди у розмірі 0 USD. Це відповідає дивідендній дохідності 0 %.

Avenue Therapeutics призначається до сектора "Здоров'я".

Щоб отримати останній дивіденд від Avenue Therapeutics від 22.09.2024 у розмірі 0 USD, тобі потрібно було мати акцію в портфелі до дня Ex-Tag 22.09.2024.

Останню дивіденду було виплачено 22.09.2024.

У 2023 році компанія Avenue Therapeutics виплатила 0 USD у вигляді дивідендів.

Дивіденди Avenue Therapeutics виплачуються у USD.